Symbols / CURE
CURE Chart
About
The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index includes domestic companies from the healthcare sector, which includes: pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and health care technology. It is non-diversified.
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | — | Cash/sh | — | Dividend Yield | 114.00% |
| Payout | — | Employees | — | IPO | — |
| P/E | 28.80 | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | 123.80 | 52W Low | 66.00 |
| Beta | — | Avg Volume | 62.72K | Volume | 19.59K |
| Target Price | — | Recom | — | Prev Close | $115.57 |
| Price | $118.17 | Change | 2.25% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
No analyst ratings or price targets available.
- Myeloma Survivor Shares “Justifiable Hope” After 8-Year Remission - CUREtoday.com Wed, 18 Feb 2026 19
- Hims & Hers $1.2 Billion Global Leap: Can Eucalyptus Cure its GLP-1 Ills? - 24/7 Wall St. Fri, 20 Feb 2026 16
- The Hair-Loss Cure That Just Sent This Stock Exploding 24%--Is Big Pharma Paying Attention? - Yahoo Finance Wed, 03 Dec 2025 08
- Top Cancer Stocks for 2026 and How to Invest - The Motley Fool hu, 12 Feb 2026 08
- CureVac is now part of the BioNTech Group - CureVac hu, 18 Dec 2025 11
- Understanding Momentum Shifts in (CURE) - Stock Traders Daily Fri, 13 Feb 2026 08
- The Shutdown’s End Is a Band-Aid, Not a Cure, for What Ails the Stock Market - Barron's Mon, 10 Nov 2025 08
- These Stocks Could Be Catalysts for CURE - ETF Trends ue, 04 Nov 2025 08
- CURE: The Leveraged ETF That Turbocharges The Leading U.S. Healthcare Stocks (CURE) - Seeking Alpha Fri, 12 Dec 2025 08
- IceCure Medical (NASDAQ: ICCM) gets Nasdaq bid-price notice; 180 days to regain $1.00 - Stock Titan Fri, 14 Nov 2025 08
- CRISIS WITHOUT CURE: A Marxist analysis of the impending stock market crash - In Defence of Marxism hu, 23 Oct 2025 07
- IceCure Medical stock jumps as FDA greenlights breast cancer cryoablation treatment - Fierce Biotech Mon, 06 Oct 2025 07
- Oracle’s (ORCL) AI in Cancer Research Push Doesn’t Cure Stock Sell-Off - TipRanks Sat, 08 Nov 2025 08
- Stock market slump offers potential cure to stubbornly high US inflation - S&P Global Fri, 21 Mar 2025 07
- Forget AI Stocks: This Biotech Could Cure What AI Can't Touch - The Motley Fool hu, 29 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for CURE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|